Related references
Note: Only part of the references are listed.Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs
Claudia Binda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Risk factors for the development of pedal edema in patients using pramipexole
Galit Kleiner-Fisman et al.
ARCHIVES OF NEUROLOGY (2007)
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease
Mark F. Lew et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease
Astrid Thomas et al.
JOURNAL OF NEUROLOGY (2006)
Targeting adenosine A2A receptors in Parkinson's disease
Michael A. Schwarzschild et al.
TRENDS IN NEUROSCIENCES (2006)
Structure of the human mitochondrial monoamine oxidase B -: New chemical implications for neuroprotectant drug design
C. Binda et al.
NEUROLOGY (2006)
Safinamide - From molecular targets to a new anti-Parkinson drug
C. Caccia et al.
NEUROLOGY (2006)
Symptom relief in Parkinson disease by safinamide - Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
F. Stocchi et al.
NEUROLOGY (2006)
Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology
R Pahwa et al.
NEUROLOGY (2006)
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys
P Samadi et al.
MOVEMENT DISORDERS (2005)
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations
J Jankovic
MOVEMENT DISORDERS (2005)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
G Van Camp et al.
LANCET (2004)
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations:: A 3-month, randomized, placebo-controlled study
CH Waters et al.
MOVEMENT DISORDERS (2004)
Improvement of motor function in early Parkinson disease by safinamide
F Stocchi et al.
NEUROLOGY (2004)
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity
A Marzo et al.
PHARMACOLOGICAL RESEARCH (2004)
Impact of placebo assignment in clinical trials of Parkinson's disease
CG Goetz et al.
MOVEMENT DISORDERS (2003)
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs
EK Perry et al.
ANNALS OF NEUROLOGY (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment
BM Ravina et al.
NEUROLOGY (2003)
[123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease
A Winogrodzka et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2003)
Neuroprotection in Parkinson's disease: Clinical trials
F Stocchi et al.
ANNALS OF NEUROLOGY (2003)
Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease
KS McNaught et al.
ANNALS OF NEUROLOGY (2003)
Oxidative stress in Parkinson's disease
P Jenner
ANNALS OF NEUROLOGY (2003)
Neuroinflammatory processes in Parkinson's disease
S Hunot et al.
ANNALS OF NEUROLOGY (2003)
New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients:: a PET - [11C]raclopride study
RM Moresco et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD
M Ulivelli et al.
NEUROLOGY (2002)
Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study
P Del Dotto et al.
MOVEMENT DISORDERS (2001)
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
MBH Youdim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Share Paper
